{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T04:56:59Z","timestamp":1781758619916,"version":"3.54.5"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T00:00:00Z","timestamp":1763942400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T00:00:00Z","timestamp":1766966400000},"content-version":"vor","delay-in-days":35,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Bisa Research Grant of Keimyung University","award":["grant number 20230704"],"award-info":[{"award-number":["grant number 20230704"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Background Selenium (Se) status may influence activity and treatment response in thyroid eye disease (TED), but evidence from Se\u2011sufficient regions is limited. We aimed to evaluate the association between serum Se levels and clinical and serological outcomes in patients with TED treated with intravenous steroid therapy and Se supplementation. Serum Se increased from 125.05 to 167.75\u00a0\u00b5g\/L throughout the follow\u2011up period (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.001). Baseline Se correlated inversely with Clinical Activity Score (CAS) change at 2 months (\u03c1=\u22120.308;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.047). A baseline Se threshold of 147.53\u00a0\u00b5g\/L showed modest discrimination for \u2265\u20092-point CAS reduction (area under the curve [AUC] 0.653; sensitivity 50.0%; specificity 85.7%; positive predictive value 63.6%; negative predictive value 77.4%). Patients with Se\u2009\u2265\u2009147.53\u00a0\u00b5g\/L showed greater CAS reduction than those with lower levels (median \u2212\u20092.0 vs. \u2212\u20091.0,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.012), and retained lower baseline\u2011adjusted final CAS in a rank\u2011based analysis of covariance (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.017). Se levels were not significantly correlated with thyroid-stimulating hormone receptor antibody or thyroid-stimulating immunoglobulin changes. In a Se\u2011replete cohort receiving intravenous steroid plus Se, higher pretreatment Se was associated with greater CAS improvement. Given the modest AUC and limited power (59.5%), these hypothesis\u2011generating findings warrant prospective validation.\n                  <\/jats:p>","DOI":"10.1038\/s41598-025-29716-6","type":"journal-article","created":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T13:05:07Z","timestamp":1763989507000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Baseline selenium is associated with response to intravenous Methylprednisolone with selenium supplementation for thyroid eye disease in a selenium-sufficient area"],"prefix":"10.1038","volume":"15","author":[{"given":"Su Min","family":"Sung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong Cheol","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,24]]},"reference":[{"key":"29716_CR1","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1097\/IOP.0000000000001136","volume":"34","author":"M Marin\u00f2","year":"2018","unstructured":"Marin\u00f2, M. et al. Selenium in graves hyperthyroidism and orbitopathy. Ophthal Plast. Reconstr. Surg. 34, 105\u2013110 (2018).","journal-title":"Ophthal Plast. Reconstr. Surg."},{"key":"29716_CR2","doi-asserted-by":"crossref","unstructured":"Duntas, L. H. The evolving role of selenium in the treatment of Graves\u2019 disease and ophthalmopathy. J. Thyroid. Res. 736161 (2012).","DOI":"10.1155\/2012\/736161"},{"key":"29716_CR3","doi-asserted-by":"crossref","unstructured":"Kim, T. H. et al. Serum selenium levels in patients with graves disease: associations with clinical activity and severity in a retrospective case-control study. Korean J. Ophthalmol. 36, 36\u201343 (2022).","DOI":"10.3341\/kjo.2021.0146"},{"key":"29716_CR4","doi-asserted-by":"publisher","first-page":"e000713","DOI":"10.1136\/bmjophth-2021-000713","volume":"6","author":"M Lumyongsatien","year":"2021","unstructured":"Lumyongsatien, M. et al. Relative selenium insufficiency is a risk factor for developing severe graves\u2019 orbitopathy: a case\u2013control study. BMJ Open. Ophthalmol. 6, e000713 (2021).","journal-title":"BMJ Open. Ophthalmol."},{"key":"29716_CR5","doi-asserted-by":"publisher","first-page":"154998","DOI":"10.1016\/j.cyto.2020.154998","volume":"127","author":"M He","year":"2020","unstructured":"He, M. et al. The potential markers involved in newly diagnosed graves\u2019 disease and the development of active graves\u2019 orbitopathy. Cytokine 127, 154998 (2020).","journal-title":"Cytokine"},{"key":"29716_CR6","doi-asserted-by":"publisher","first-page":"133","DOI":"10.55133\/eji.310114","volume":"31","author":"GA Hasanin","year":"2024","unstructured":"Hasanin, G. A. et al. Serum selenium status in Egyptians patients who had graves\u2019 disease with and without ophthalmopathy. Egypt. J. Immunol. 31, 133\u2013142 (2024).","journal-title":"Egypt. J. Immunol."},{"key":"29716_CR7","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1159\/000442440","volume":"5","author":"N Dehina","year":"2016","unstructured":"Dehina, N., Hofmann, P. J., Behrends, T., Eckstein, A. & Schomburg, L. Lack of association between selenium status and disease severity and activity in patients with graves\u2019 ophthalmopathy. Eur. Thyroid J. 5, 57\u201364 (2016).","journal-title":"Eur. Thyroid J."},{"key":"29716_CR8","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1056\/NEJMoa1012985","volume":"364","author":"C Marcocci","year":"2011","unstructured":"Marcocci, C. et al. Selenium and the course of mild graves\u2019 orbitopathy. N Engl. J. Med. 364, 1920\u20131931 (2011).","journal-title":"N Engl. J. Med."},{"key":"29716_CR9","doi-asserted-by":"crossref","unstructured":"Ventura, M., Melo, M. & Carrilho, F. Selenium and thyroid disease: from pathophysiology to treatment. Int. J. Endocrinol. 1297658 (2017).","DOI":"10.1155\/2017\/1297658"},{"key":"29716_CR10","doi-asserted-by":"crossref","unstructured":"Bartalena, L. et al. The 2021 European group on graves\u2019 orbitopathy (EUGOGO) clinical practice guidelines for the medical management of graves\u2019 orbitopathy. Eur J. Endocrinol 185, G43\u2013G67 (2021).","DOI":"10.1530\/EJE-21-0861"},{"key":"29716_CR11","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1159\/000494837","volume":"8","author":"R Negro","year":"2019","unstructured":"Negro, R., Heged\u00fcs, L., Attanasio, R., Papini, E. & Winther, K. H. A 2018 European thyroid association survey on the use of selenium supplementation in graves\u2019 hyperthyroidism and graves\u2019 orbitopathy. Eur. Thyroid J. 8, 7\u201315 (2019).","journal-title":"Eur. Thyroid J."},{"key":"29716_CR12","doi-asserted-by":"publisher","first-page":"281","DOI":"10.2174\/157340607780620662","volume":"3","author":"T Wertenbruch","year":"2007","unstructured":"Wertenbruch, T. et al. Serum selenium levels in patients with remission and relapse of graves\u2019 disease. Med. Chem. 3, 281\u2013284 (2007).","journal-title":"Med. Chem."},{"key":"29716_CR13","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/S0140-6736(00)02490-9","volume":"356","author":"MP Rayman","year":"2000","unstructured":"Rayman, M. P. The importance of selenium to human health. Lancet 356, 233\u2013241 (2000).","journal-title":"Lancet"},{"key":"29716_CR14","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.abb.2015.06.024","volume":"595","author":"H Steinbrenner","year":"2016","unstructured":"Steinbrenner, H., Speckmann, B. & Klotz, L. O. Selenoproteins: antioxidant selenoenzymes and beyond. Arch. Biochem. Biophys. 595, 113\u2013119 (2016).","journal-title":"Arch. Biochem. Biophys."},{"key":"29716_CR15","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1089\/thy.2005.15.841","volume":"15","author":"J K\u00f6hrle","year":"2005","unstructured":"K\u00f6hrle, J. Selenium and the control of thyroid hormone metabolism. Thyroid 15, 841\u2013853 (2005).","journal-title":"Thyroid"},{"key":"29716_CR16","doi-asserted-by":"publisher","first-page":"1133000","DOI":"10.3389\/fendo.2023.1133000","volume":"14","author":"F Wang","year":"2023","unstructured":"Wang, F. et al. Selenium and thyroid diseases. Front. Endocrinol. (Lausanne). 14, 1133000 (2023).","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"29716_CR17","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1210\/jc.2018-01713","volume":"104","author":"Y Wang","year":"2019","unstructured":"Wang, Y. et al. Role of selenium intake for risk and development of hyperthyroidism. J. Clin. Endocrinol. Metab. 104, 568\u2013580 (2019).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"29716_CR18","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1159\/000381768","volume":"4","author":"J Calissendorff","year":"2015","unstructured":"Calissendorff, J., Mikulski, E., Larsen, E. H. & M\u00f6ller, M. A prospective investigation of graves\u2019 disease and selenium: thyroid hormones, auto-antibodies and self-rated symptoms. Eur. Thyroid J. 4, 93\u201398 (2015).","journal-title":"Eur. Thyroid J."},{"key":"29716_CR19","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1007\/s12020-016-1226-9","volume":"58","author":"G Rotondo Dottore","year":"2017","unstructured":"Rotondo Dottore, G. et al. Selenium rescues orbital fibroblasts from cell death induced by hydrogen peroxide: another molecular basis for the effects of selenium in graves\u2019 orbitopathy. Endocrine 58, 386\u2013389 (2017).","journal-title":"Endocrine"},{"key":"29716_CR20","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1055\/s-0042-110491","volume":"48","author":"L Wang","year":"2016","unstructured":"Wang, L. et al. Effect of selenium supplementation on recurrent hyperthyroidism caused by graves\u2019 disease: a prospective pilot study. Horm. Metab. Res. 48, 559\u2013564 (2016).","journal-title":"Horm. Metab. Res."},{"key":"29716_CR21","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1080\/01676830.2024.2315566","volume":"43","author":"P Potita","year":"2024","unstructured":"Potita, P., Pruksakorn, V., Srichomkwun, P., Kingpetch, K. & Saonanon, P. Selenium supplementation in inactive moderate to severe graves\u2019 orbitopathy patients: a randomized controlled trial. Orbit 43, 329\u2013336 (2024).","journal-title":"Orbit"},{"key":"29716_CR22","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1016\/S0140-6736(11)61452-9","volume":"379","author":"MP Rayman","year":"2012","unstructured":"Rayman, M. P. Selenium and human health. Lancet 379, 1256\u20131268 (2012).","journal-title":"Lancet"},{"key":"29716_CR23","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1002\/ejhf.1644","volume":"22","author":"N Bomer","year":"2020","unstructured":"Bomer, N. et al. Selenium and outcome in heart failure. Eur. J. Heart Fail. 22, 1415\u20131423 (2020).","journal-title":"Eur. J. Heart Fail."},{"key":"29716_CR24","doi-asserted-by":"publisher","first-page":"13640","DOI":"10.1074\/jbc.M300755200","volume":"278","author":"KE Hill","year":"2003","unstructured":"Hill, K. E. et al. Deletion of Selenoprotein P alters distribution of selenium in the mouse. J. Biol. Chem. 278, 13640\u201313646 (2003).","journal-title":"J. Biol. Chem."},{"key":"29716_CR25","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1079\/BJN19930057","volume":"69","author":"CD Thomson","year":"1993","unstructured":"Thomson, C. D., Robinson, M. F., Butler, J. A. & Whanger, P. D. Long-term supplementation with selenate and selenomethionine: selenium and glutathione peroxidase (EC 1.11.1.9) in blood components of new Zealand women. Br. J. Nutr. 69, 577\u2013588 (1993).","journal-title":"Br. J. Nutr."},{"key":"29716_CR26","doi-asserted-by":"publisher","first-page":"97","DOI":"10.17925\/USE.2015.11.02.97","volume":"11","author":"LH Duntas","year":"2015","unstructured":"Duntas, L. H. & Hubalewska-Dydejczyk, A. Selenium and inflammation\u2014potential use and future perspectives. US Endocrinol. 11, 97\u2013102 (2015).","journal-title":"US Endocrinol."},{"key":"29716_CR27","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1590\/2359-3997000000309","volume":"61","author":"MAF Federige","year":"2017","unstructured":"Federige, M. A. F. et al. Serum selenium and selenoprotein-P levels in autoimmune thyroid diseases patients in a select center: a transversal study. Arch. Endocrinol. Metab. 61, 600\u2013607 (2017).","journal-title":"Arch. Endocrinol. Metab."},{"key":"29716_CR28","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1039\/C5MT00211G","volume":"7","author":"J Martitz","year":"2015","unstructured":"Martitz, J. et al. Gene-specific regulation of hepatic Selenoprotein expression by interleukin-6. Metallomics 7, 1515\u20131521 (2015).","journal-title":"Metallomics"},{"key":"29716_CR29","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.freeradbiomed.2024.06.027","volume":"222","author":"U Alehagen","year":"2024","unstructured":"Alehagen, U. et al. Selenoprotein P increases upon selenium and coenzyme Q(10) supplementation and is associated with telomere length, quality of life and reduced inflammation and mortality. Free Radic Biol. Med. 222, 403\u2013413 (2024).","journal-title":"Free Radic Biol. Med."},{"key":"29716_CR30","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1001\/archinternmed.2007.74","volume":"168","author":"J Bleys","year":"2008","unstructured":"Bleys, J., Navas-Acien, A. & Guallar, E. Serum selenium levels and all-cause, cancer, and cardiovascular mortality among US adults. Arch. Intern. Med. 168, 404\u2013410 (2008).","journal-title":"Arch. Intern. Med."},{"key":"29716_CR31","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1001\/archinternmed.2009.495","volume":"170","author":"JK MacFarquhar","year":"2010","unstructured":"MacFarquhar, J. K. et al. Acute selenium toxicity associated with a dietary supplement. Arch. Intern. Med. 170, 256\u2013261 (2010).","journal-title":"Arch. Intern. Med."},{"key":"29716_CR32","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1001\/jama.2008.864","volume":"301","author":"SM Lippman","year":"2009","unstructured":"Lippman, S. M. et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the selenium and vitamin E cancer prevention trial (SELECT). JAMA 301, 39\u201351 (2009).","journal-title":"JAMA"},{"key":"29716_CR33","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/S0889-8529(18)30485-7","volume":"16","author":"RS Bahn","year":"1987","unstructured":"Bahn, R. S. & Gorman, C. A. Choice of therapy and criteria for assessing treatment outcome in thyroid-associated ophthalmopathy. Endocrinol. Metab. Clin. North. Am. 16, 391\u2013407 (1987).","journal-title":"Endocrinol. Metab. Clin. North. Am."},{"key":"29716_CR34","first-page":"312","volume":"15","author":"YJ Kwak","year":"1974","unstructured":"Kwak, Y. J. Normal range of exophthalmos in Koreans. J. Korean Ophthalmol. Soc. 15, 312\u2013315 (1974).","journal-title":"J. Korean Ophthalmol. Soc."},{"key":"29716_CR35","first-page":"305","volume":"15","author":"TM Chung","year":"1974","unstructured":"Chung, T. M. The exophthalmometry, extraorbital width and height of lid fissure of Koreans. J. Korean Ophthalmol. Soc. 15, 305\u2013311 (1974).","journal-title":"J. Korean Ophthalmol. Soc."},{"key":"29716_CR36","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1046\/j.1365-2265.1997.2331047.x","volume":"47","author":"MP Mourits","year":"1997","unstructured":"Mourits, M. P., Prummel, M. F., Wiersinga, W. M. & Koornneef, L. Clinical activity score as a guide in the management of patients with graves\u2019 ophthalmopathy. Clin. Endocrinol. (Oxf). 47, 9\u201314 (1997).","journal-title":"Clin. Endocrinol. (Oxf)"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-29716-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-29716-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-29716-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T19:04:11Z","timestamp":1777403051000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-29716-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,24]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["29716"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-29716-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,24]]},"assertion":[{"value":"23 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflicts of interest related to this work. This study was supported by Keimyung University Bisa Research Grant (Project No: 20230704). No other financial or non-financial relationships are disclosed.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"45276"}}